 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...13141516171819202122232425» |
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma (clinicaltrials.gov) - Mar 9, 2015
P2, N=42, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2006 --> Sep 2013
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
New P1 trial: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Mar 9, 2015
P1, N=60, Recruiting, Sponsor: Regeneron Pharmaceuticals
- | IMA950 / Immatics, University Hospitals of Geneva
Trial completion: CRUK-CR0902-11: Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Mar 7, 2015
P1, N=45, Completed, Sponsor: Cancer Research UK
Trial primary completion date: Dec 2006 --> Sep 2013 Active, not recruiting --> Completed
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment closed: Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma (clinicaltrials.gov) - Feb 27, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap, Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion: Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms (clinicaltrials.gov) - Feb 27, 2015
P=N/A, N=16, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial completion: Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer (clinicaltrials.gov) - Feb 23, 2015
P2, N=8, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change, Trial primary completion date: CML 0206: Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (clinicaltrials.gov) - Feb 19, 2015
P2, N=44, Completed, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=69 --> 44 | Trial primary completion date: Jul 2010 --> Jul 2014
- || Leukine (sargramostim) / Partner Therap
New P3 trial: GRID: GM-CSF to Decrease ICU Acquired Infections (clinicaltrials.gov) - Feb 11, 2015
P3, N=488, Not yet recruiting, Sponsor: Hospices Civils de Lyon
- BB-MPI-03 / Benovus Bio
Enrollment open: BBMPI03: Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (clinicaltrials.gov) - Feb 10, 2015
P1, N=30, Recruiting, Sponsor: Benovus Bio, Inc.
Active, not recruiting --> Completed | N=69 --> 44 | Trial primary completion date: Jul 2010 --> Jul 2014 Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Feb 6, 2015
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2015 --> Jan 2016
- Bexxar (iodine I 131 tositumomab) / GSK
Trial completion: Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 5, 2015
P2, N=25, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jan 2015 --> Jan 2016 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) - Feb 2, 2015
P2, N=40, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Jan 2016
- || Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 29, 2015
P2, N=130, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Aug 2015 --> Aug 2016
- Leukine (sargramostim) / Partner Therap
Trial initiation date, IO biomarker: The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - Jan 15, 2015
P1, N=20, Not yet recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Aug 2015 --> Aug 2016 Initiation date: Dec 2014 --> Mar 2015
- | Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2/3 trial, PD(L)-1 Biomarker: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Jan 15, 2015
P2/3, N=400, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- |||| Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 13, 2015
P2, N=60, Completed, Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2014 --> Mar 2015 Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2014
- ||| Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Trial initiation date: Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (clinicaltrials.gov) - Jan 12, 2015
P2, N=54, Not yet recruiting, Sponsor: Lawrence Fong
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2014 Initiation date: Aug 2014 --> Mar 2015
- Clinical: NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders (clinicaltrials.gov) - Jan 9, 2015
P2, N=41, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Initiation date: Aug 2014 --> Mar 2015 Trial primary completion date: Nov 2014 --> Nov 2015
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
New P1 trial: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy (clinicaltrials.gov) - Jan 8, 2015
P1, N=18, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- Leukine (sargramostim) / Partner Therap
Enrollment change, Trial termination, Trial primary completion date: Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy (clinicaltrials.gov) - Dec 24, 2014
P1, N=21, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Nov 2015 N=42 --> 21 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2010 --> Dec 2009
- Leukine (sargramostim) / Partner Therap
Trial completion, Trial primary completion date: GPAD-2: Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease (clinicaltrials.gov) - Dec 24, 2014
P2, N=159, Completed, Sponsor: Emory University
N=42 --> 21 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2010 --> Dec 2009 Active, not recruiting --> Completed | Trial primary completion date: Jan 2013 --> Mar 2014
- Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma (clinicaltrials.gov) - Dec 24, 2014
P2, N=0, Completed, Sponsor: Craig L Slingluff, Jr
Active, not recruiting --> Completed | Trial primary completion date: Jan 2013 --> Mar 2014 Active, not recruiting --> Completed
- BiovaxID (dasiprotimut-T) / National Cancer Institute, Accentia
Trial primary completion date: Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (clinicaltrials.gov) - Dec 19, 2014
P2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Aug 2005
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Leukine (sargramostim) / Partner Therap
Trial completion, Surgery, Metastases: Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma (clinicaltrials.gov) - Dec 19, 2014
P1, N=0, Completed, Sponsor: Craig L Slingluff, Jr
Trial primary completion date: Jun 2017 --> Aug 2005 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial completion, Surgery, Metastases: Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 19, 2014
P2, N=7, Completed, Sponsor: University of Virginia
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change, Metastases: Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma (clinicaltrials.gov) - Dec 19, 2014
P2, N=40, Completed, Sponsor: University of Virginia
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=54 --> 40
- BiovaxID (dasiprotimut-T) / National Cancer Institute, Accentia
Enrollment closed, Trial primary completion date: Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (clinicaltrials.gov) - Dec 17, 2014
P2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=54 --> 40 Completed --> Active, not recruiting | Trial primary completion date: Aug 2005 --> Jun 2017
- | UV1 / Ultimovacs
Enrollment open, Combination therapy, Metastases: Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (clinicaltrials.gov) - Dec 10, 2014
P1/2, N=20, Recruiting, Sponsor: Ultimovacs AS
Completed --> Active, not recruiting | Trial primary completion date: Aug 2005 --> Jun 2017 Not yet recruiting --> Recruiting
- Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Dec 9, 2014
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Apr 2016
- | Vacc-4x / Bionor
Enrollment closed, Epigenetic controller: Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (clinicaltrials.gov) - Dec 9, 2014
P1/2, N=26, Active, not recruiting, Sponsor: Bionor Immuno AS
Trial primary completion date: Jun 2015 --> Apr 2016 Recruiting --> Active, not recruiting
- UV1 / Ultimovacs
Enrollment closed, Trial primary completion date, Metastases: A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer (clinicaltrials.gov) - Dec 9, 2014
P1/2, N=21, Active, not recruiting, Sponsor: Ultimovacs AS
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jul 2015
- Enrollment open: HER2-Peptide Vaccination of Patients With Solid Tumors (clinicaltrials.gov) - Dec 5, 2014
P1, N=12, Recruiting, Sponsor: Technische Universit
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jul 2015 Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Nov 28, 2014
P2, N=52, Active, not recruiting, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2015 --> Jan 2016
- ||||| Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
New P2 trial: Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (clinicaltrials.gov) - Nov 23, 2014
P2, N=100, Recruiting, Sponsor: Cancer Insight, LLC
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Enrollment open, Trial initiation date: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (clinicaltrials.gov) - Nov 23, 2014
P1/2, N=40, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Jan 2015 --> Jan 2016 Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma (clinicaltrials.gov) - Nov 20, 2014
P1/2, N=39, Completed, Sponsor: University of Virginia
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial suspension: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Nov 12, 2014
P1, N=12, Suspended, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Recruiting --> Suspended
- | New P1 trial: HER2-Peptide Vaccination of Patients With Solid Tumors (clinicaltrials.gov) - Oct 28, 2014
P1, N=12, Not yet recruiting, Sponsor: Technische Universit
- | UV1 / Ultimovacs
New P1/2 trial, Combination therapy, Metastases: Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (clinicaltrials.gov) - Oct 27, 2014
P1/2, N=20, Not yet recruiting, Sponsor: Ultimovacs AS
- temozolomide / Generic mfg.
Enrollment open, Immunomodulating: GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov) - Oct 24, 2014
P1, N=20, Recruiting, Sponsor: immatics Biotechnologies GmbH
Recruiting --> Suspended Not yet recruiting --> Recruiting
- Clinical: NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders (clinicaltrials.gov) - Oct 17, 2014
P2, N=41, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2013 --> Nov 2014
- temozolomide / Generic mfg.
Trial initiation date, Immunomodulating: GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov) - Oct 15, 2014
P1, N=20, Not yet recruiting, Sponsor: immatics Biotechnologies GmbH
Trial primary completion date: Oct 2013 --> Nov 2014 Initiation date: Jul 2014 --> Oct 2014
- ||||||| Imlygic (talimogene laherparepvec) / Amgen
Trial completion: OPTiM: Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma (clinicaltrials.gov) - Oct 2, 2014
P3, N=439, Completed, Sponsor: BioVex Limited
Initiation date: Jul 2014 --> Oct 2014 Active, not recruiting --> Completed
- || Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 30, 2014
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: May 2015 --> May 2016
- || Leukine (sargramostim) / Partner Therap
Trial primary completion date: Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI (clinicaltrials.gov) - Sep 29, 2014
P2, N=56, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Dec 2014 --> Dec 2015
- SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial primary completion date: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Sep 28, 2014
P1, N=9, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Sep 2014 --> May 2014
- | Leukine (sargramostim) / Partner Therap
New P1 trial, IO biomarker: The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=20, Not yet recruiting, Sponsor: University of Colorado, Denver
- ||||| Rintega (rindopepimut) / Celldex
Enrollment closed: Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Sep 28, 2014
P3, N=700, Active, not recruiting, Sponsor: Celldex Therapeutics
Trial primary completion date: Sep 2014 --> May 2014 Recruiting --> Active, not recruiting
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment open, Trial initiation date, Trial primary completion date: A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas (clinicaltrials.gov) - Sep 22, 2014
P1, N=36, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Sep 2014 | Trial primary completion date: May 2020 --> Sep 2020
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Leukine (Sargramostim) for Parkinson's Disease (clinicaltrials.gov) - Sep 19, 2014
P1, N=32, Recruiting, Sponsor: Howard Gendelman, MD
Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Sep 2014 | Trial primary completion date: May 2020 --> Sep 2020 Trial primary completion date: Jan 2015 --> Sep 2015